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Given the increasing demand for health care interventions and
limited resources, there is a growing interest in evidence on va-
lue for money. Economic evaluation serves to demonstrate the
value for money of health care interventions. It addresses the
question of whether a new health intervention is worth funding
when compared with other possible uses of the same resources,
to ensure that efﬁciency has been attained. Efﬁciency implies
that we make choices that maximize beneﬁts (health gains)
from limited resources (Palmer and Torgerson, 1999). In eco-
nomic evaluation the costs and consequences of alternative
interventions are compared (Drummond et al., 2005). Pharma-
coeconomics is the economic evaluation of pharmaceuticals.
According to the American Society of Hospital Pharmacists
(ASHP) a formulary system should be developed and imple-
mented in hospital settings to promote the rational, evi-
dence-based, clinically appropriate, safe, and cost-effective
use of medications in order to optimize patient care (ASHP,
2008). The ASHP also recommends that the pharmacy and
therapeutics (P&T) committee is responsible for administering
the formulary system.
Many countries have begun to use economic evidence to
support decisions on licensing, pricing, reimbursement, or
addition to the formulary (Taylor et al., 2004). Formal and
informal guidelines for the submission of pharmacoeconomics
data to support reimbursement or pricing decisions were issued
in many countries (Hjelmgren et al., 2001). Guidelines for the
submission of pharmacoeconomics data to help P&T commit-
tees make informed decisions about which products to include
on health plan formularies have been proposed (Marshall
et al., 2008; Sullivan et al., 2001).
In Saudi Arabia, it is not mandatory to submit cost effec-
tiveness evidence to support licensing or addition to the formu-
lary decisions, however, data will be considered if submitted. A
survey of P&T committee members in Riyadh, Saudi Arabia
indicated the reason for the limited use of pharmacoeconomic
evidence when making formulary decisions is lack of expertise
and lack of resources (Alsultan, 2011). There is no publication
yet that aims to guide Saudi decision makers when need arises
to use pharmacoeconomic evidence. This paper intended to
provide Saudi decision makers with a clear set of best practice
methodological recommendations to help in increasing the useof pharmacoeconomic evidence in the formulary decision mak-
ing process. The intended audience for the guidelines are deci-
sion makers at the P&T committees of Saudi hospitals, the
paper, however, is still relevant to decision makers at the Min-
istry of Health (MoH) and Saudi Food and Drug Authority.
As the target audience may not necessarily be an expert in
the area of pharmacoeconomics, the recommendations were
deliberately kept brief and written in non-technical language.
If pharmacoeconomics evidence is required to support for-
mulary decision making process in Saudi Arabia, two situa-
tions can be identiﬁed: conduct a new pharmacoeconomic
evaluation or use the results of existing pharmacoeconomic
evaluation. The best practice recommendations for both situa-
tions are described below.2. Conduct a new pharmacoeconomic evaluation
Approaches to conduct a full economic evaluation can be cat-
egorized as (i) either trial-based studies using patient-level data
or (ii) decision analytic modelling based on secondary data or
institution speciﬁc data. In both cases, the initiator of the study
has to consider a few important aspects of the evaluation de-
sign. This section will focus on three of these: the research
question, outcome and costs measurement and valuation,
and presentation of results and analysis.
2.1. Deﬁne the evaluation question
The evaluation question could be structured around three
items: perspective, choice of alternative medications, and
choice of analysis technique. The analysis perspective dictates
which costs and beneﬁts are collected and assessed (Drum-
mond et al., 2005). Possible viewpoints include those of the
hospital, the insurance company, the patient, and society itself.
The use of societal perspective is encouraged because it is wide
enough to ensure that all costs and outcomes are included.
Ignoring important costs and beneﬁts in an economic analysis
will lead to an inefﬁcient allocation of resources (Jo¨nsson,
2009). In Saudi Arabia, health care services are provided pri-
marily by the MoH and other government agencies such as
the Ministry of Defence and Aviation, the National Guard,
and the Ministry of Interior. Services offered by these hospitals
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Table 1 Perspectives of economic evaluations and their
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The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia 189are free of charge for all eligible citizens. In addition, large pri-
vate companies are obliged to buy health cover for their
employees. If adapting a social perspective proves difﬁcult,
the adaptation of central health service provider such as
MoH is advisable more than adapting the narrow perspective
of one governmental hospital for instance. This means costs
and outcomes not relevant to the MoH such as costs incurred
by reduced productivity of patients and their family as a result
of illness, death or treatment would be excluded (Table 1).
However, an indication of the nature and likely magnitude
of any excluded beneﬁts and costs from the patients’ perspec-
tive is also advisable.
Pharmacoeconomic analysis involves a comparison be-
tween at least two alternative medications (Drummond et al.,
2005). The new drug should be compared with the most com-
monly prescribed treatments used for the same indication in
the institution including non-drug therapies and no-treatment.
If the most prescribed treatment is not the most efﬁcacious,
then the treatment with the best proven efﬁcacy for the same
indication should also be included.
Cost-minimisation analysis (CMA), cost-effectiveness anal-
ysis (CEA), cost-utility analysis (CUA), and cost beneﬁt anal-
ysis (CBA) represent the main pharmacoeconomic evaluation
techniques. All analyses identify and quantify costs in the same
manner but measure and value health outcome, beneﬁts, or
outputs differently. Table 2 illustrates the differences between
types of pharmacoeconomic evaluation and gives examples on
each type.
In cost minimisation analysis, outcomes of the two [or
more] comparators are assumed to be equal, based on evidence
to that effect, thereby resulting in an assessment based solely
on comparative cost. When two medications are different in
their effects on patient outcomes, the authors recommend
the use CUA, CEA, and/or CBA. CBA is grounded in eco-
nomic welfare theory, however, there are many controversies
associated with monetary valuation of clinical and non-clinical
outcomes (Drummond et al., 2005; Johannesson et al., 1996)which explain why it is less commonly used than CEA and
CUA. The use of CUA or CBA has the advantage that they
facilitate the comparison of interventions and the allocation
of resources across different medical conditions. On the other
hand, the results from CEA facilitate the comparison only be-
tween interventions that produce the same (or very similar)
clinical outcomes (Oliver et al., 2002). Another technique
which is complementary not as a variant or replacement to
pharmacoeconomic techniques is budget impact analysis
(BIA) (Mauskopf et al., 2007). Whereas, pharmacoeconomic
evaluation measures the costs and outcomes of alternative
technologies to estimate their economic efﬁciency, BIA ad-
dresses the ﬁnancial consequences related to the uptake and
diffusion of interventions to assess their affordability (Table 2).
Readers can ﬁnd more details on this technique elsewhere
(Mauskopf et al., 2007).
2.2. Outcomes measurement and valuation
In CEA outcomes are measured in natural health effectiveness
units, such as life years gained, symptom-free days, or bad clin-
ical events avoided. A surrogate endpoint of a clinical trial is a
laboratory measurement or a physical sign (a reduction in
blood cholesterol level, for example) used as a substitute for
a clinically meaningful endpoint such as life saved, death
avoided (Drummond et al., 2005). As effects of new medica-
tions on surrogate end points often do not predict the true clin-
ical effects of interventions (Fleming and Demets, 1996;
Moynihan, 2011), it is advisable to use ﬁnal and patient ori-
ented outcomes rather than intermediate disease oriented out-
comes. When this is not possible and there is a requirement to
use a surrogate outcome, assessment of whether surrogate
variables actually measure what they are supposed to measure
(i.e. their validity) is required. Evidence on effectiveness should
be derived from high quality, up-to-date systematic reviews or
adequately powered randomised controlled trials identiﬁed
through a comprehensive literature review. The generalizabil-
ity of the collected evidence and its applicability to local con-
text should be assessed. This should include at least the
estimation of Saudi baseline risk, case–mix, life expectancy,
and progress rate.
In CUA outcomes of alternative interventions would be ex-
pressed in terms of a single, ‘‘utility based’’ unit of measure-
ment. In a healthcare context, utility is a value that is
attached by an individual to a particular health state on the
utility scale, which generally ranges from 0, indicating death,
to 1, indicating perfect health (Brazier, 2008; Johannesson
et al., 1996). Three methods are used for direct measurement
of preference: standard gamble, time trade-off, and visual ana-
logue scale (Brazier, 2008). Instruments such as the health util-
ities index (HUI) and the EQ-5D are available for obtaining
utilities without undertaking direct measurement (Brazier,
2008; Arnold et al., 2009). The most widely used utility-based
measure is the quality-adjusted life year (QALYS) which is cal-
culated by multiplying the number of life-years gained from an
intervention by a standard weight (utilities) that reﬂects the
health related quality of life during that time. Although, there
are now a Saudi validated version of EQ-5D which can be uti-
lised locally, a P&T committee might not have the resources
(ﬁnancial and expertises) to take locally generated utility re-
sults for the study. In such a case transferability of published
utility evidence can be considered (see Section 3 below).
Table 2 Types of pharmacoeconomics evaluation.
Type Measure Outcomes measure Example from literature
Outcome Costs
CEA Yes Yes Natural unit e.g. death, life years gained,
reduction in rate of infection, stroke prevented,
disease free days
De Cock et al. (2009) compared linezolid vs
vancomycin in suspected methicillin-resistant
staphylococcus aureus nosocomial pneumonia. Outcomes
included patient cured, death avoided, and life-year gained
CUA Yes Yes Utility e.g. quality adjusted life years (QALY) Punekar et al. (2010) compared standard care with scheduled
maintenance treatment with inﬂiximab in children suﬀering
from severe active Chron’s Disease (CD) over 5 years.
The QALY estimated using the EurQol (EQ-5D) from a
European CD population
CBA Yes Yes Monetary e.g. ﬁnancial value of the beneﬁts Sullivan et al. (2004) quantiﬁed the total costs and beneﬁts of
ﬁrst-generation antihistamines (FGA). The beneﬁt associated
with FGA use was estimated using the
willingness-to-pay method. The costs of FGA-associated
sedation included lost productivity and the direct and indirect
cost of unintentional injuries
BIA No Yes – Simoens (2011) computed the budget impact of lacosamide,
a new anti-epileptic drug. The BIA calculated how a change
in the mix of anti-epileptic drugs used to treat uncontrolled
epilepsy would impact drug
spending from 2008 to 2013.
Data on the number of patients and on the market shares
of anti-epileptic drugs and unit costs of anti-epileptic drugs
were taken from Belgian sources
Cost analysis No Yes – Suh et al. (2010) estimated the total costs of ﬂuorouracil
when administered with leucovorin,
by intravenous infusion or bolus.
The costs comprised drug costs, dispensing costs,
and administration costs
(i.e. pharmacy staﬀ time spent handling
admixture, and dispensing of ﬂuorouracil)
Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), cost-beneﬁt analysis (CBA), budget impact analysis (BIA).
190 S.A. AL Aqeel, M. Al-SultanWhile monetary valuation of some clinical outcomes such
as hospitalisation is available, some beneﬁts can be measured
using the willingness to pay of individuals who beneﬁt from
the intervention. In the contingent valuation method, for
example, respondents are presented with hypothetical scenar-
ios about the interventions under evaluation and they are re-
quired to think about the contingency of an actual market
existing for these interventions and to reveal the maximum
they are willing to pay for such an intervention under evalua-
tion (O’Brien and Gafni, 1996). The net monetary gain or loss
by each alternative is then calculated and high value interven-
tions are considered to be those preferred by patients.
2.3. Costs measurement and valuation
All resources consumed in the process of providing treatment
such as drugs, equipment, disposables, medical and nursing
time, hospitalisation days, and outpatient visits should be col-
lected and estimated. The data on resources used may be gath-
ered as part of a trial, from medical records, hospital
databases, national registries or expert opinion. A word of
caution when collecting data alongside clinical trials as it is
possible that the procedures followed in the trial are not typi-
cal of care provided in every day practice (Shi et al., 2010; Min-
ers, 2008). Similarly, if the analysis used experts’ opinion to
estimate resources quantities, there is a risk that resourcesestimated are for ideal care, rather than that actually provided
in practice. If a need arises to use foreign data to estimate re-
sources use then it must be checked and validated by local
health care providers. To attach costs to resources used, mar-
ket prices, that are the prices actually paid for particular goods
or services, can be used. Prices or unit costs can be obtained
from the ﬁnance departments of particular institutions or from
national statistics, but charges (or fees) usually differ from real
costs should not to be used (Shi et al., 2010; Miners, 2008).
This requires conducting a cost analysis study (see Table 2)
to identify and measure all resources relevant to the perspec-
tive. All costs should be expressed in values for the current
year and are reported in Saudi riyals. Costs occurring beyond
one year should be discounted to present values when they oc-
cur in the future in order to reﬂect society’s rate of time pref-
erence (Shi et al., 2010; Miners, 2008). The Saudi Arabian
Monetary Agency, the central bank for the country, suggested
discount rate can be used. Alternatively the World Health
Organisation suggested discount rate of 3% can be used
(WHO, 2003).
2.4. Calculate and present results
For both the treatment and its comparator(s), the total costs
and total beneﬁts arising from their use should be presented
with their statistical distribution (mean, median, conﬁdence
Effectiveness 
Costs
Treatment A is more effective 
and less costly than B 
Treatment A is more effective 
and more costly than B Treatment A is less effective 
and more costly than B 
Treatment A is less effective 
and less costly than B 
i
iii
iiiv
Figure 1 Incremental cost-effectiveness plane for treatment A versus B.
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ratio, which is deﬁned as the mean value of the costs divided by
the mean value of the effect, can be useful in considering the
overall affordability of a medication. However, when making
a trade-off decision between two exclusive treatments, the
incremental cost-effectiveness (utility) ratios (ICERs) should
be calculated. In ICERs the difference in costs between two
treatments is divided by the difference in outcomes produced
by the same treatments. For example, a study compared the
use of everolimus versus sorafenib in renal cell carcinoma
and found that the use of everolimus resulted in life-years
gained (LYG) of 1.273 over sorafenib (Casciano et al.,
2001), however, everolimus was more costly by $81,64. The
deterministic analysis resulted in ICER of $64,155/LYG
(81,64 ‚ 1.273). That is it costs $64,155 to gain one additional
life year. The ICER can be placed on a cost-effectiveness
plane, as shown in Fig. 1 (O’Brien and Briggs, 2002). The
choice between medications with ICERSs in quadrants ii and
iii is straightforward as one therapy dominates the other in
each case (has superior effectiveness and lower cost). Medica-
tions with ICERs in quadrant i improve health but cost more
than the alternative. The decision whether or not to choose
them should be based on the level of additional resources
available and whether the additional costs of the new therapy
justify the additional beneﬁts to gain.
The results of pharmacoeconomic evaluation should be
subjected to sensitivity analysis to verify the robustness of
the conclusions and handle uncertainty (Claxton, 2008;
O’Brien and Briggs, 2002). In sensitivity analyses, key param-
eters are varied within a range in order to explore the impact of
uncertainty on the evaluation conclusions. A plausible range
can be determined by reviewing the literature, consulting ex-
pert opinion, and using a speciﬁed conﬁdence interval around
the mean (for stochastic data). Types of sensitivity analysis in-
clude one-way and multi-way analysis, threshold (or break-
even) analysis, analysis of extremes (i.e., best and worst case
scenarios), or probabilistic sensitivity analysis. The use of
probabilistic sensitivity analysis has the advantage over other
types that it can quantify the effect of uncertainty around
two or more parameters simultaneously. It is therefore, recom-
mended to be used. Sensitivity analysis results can be presentedusing cost effectiveness threshold and tornado analysis. More
advanced options such as conﬁdence ellipses and scatter plots
on the cost-effectiveness plane and cost-effectiveness accept-
ability curves can also be used (O’Brien and Briggs, 2002).
Within a probabilistic sensitivity analysis it is also helpful to
present the contribution of the uncertainty in each parameter
to overall decision uncertainty. This can be achieved using ex-
pected-value-of-information methods.
3. Transferring the results of existing pharmacoeconomic
evaluation
One could argue that this option is more suited for the Saudi
decision makers for a number of reasons. Currently there is
no nationally recognised body responsible for commissioning
and funding of pharmacoeconomic evaluation. Pharmacoeco-
nomic evaluation is usually time-consuming, expensive, and
demanding in terms of statistical sophistication and research
expertises and such expertise is limited in Saudi Arabia. This
argument is further supported by the fact that P&T committee
face budget or time constraints in decision-making process, as
a result, it is not possible to conduct a pharmacoeconomic
evaluation on every medication. Indeed, in a recent survey
involving 48 head of pharmacy departments of 11 different
hospitals in Riyadh, Saudi Arabia, respondents were asked
to indicate the data sources for pharmacoeconomic evidence
utilised in formulary decision-making. Published literatures
in peer-reviewed journals (30%), in-house expertise (5%),
pharmaceutical company (5%), and combination of the three
sources (50%) were the reported sources of evidence (Alsultan,
2011). However, the cost-effectiveness estimates of one medi-
cation might vary from place to place for a variety of reasons
such as the incidence and severity of the disease in question,
clinical practice patterns, resources utilisation, and relative
prices (Drummond et al., 2009). A review of economic evalua-
tions of medicines undertaken in Western Europe found that
the extent of variation in the estimates of the incremental
cost-effectiveness ratios between the countries to be substantial
(a twofold difference) (Barbieri et al., 2005). Therefore, accord-
ing to recent recommendations simple extrapolation of inter-
national pharmacoeconomics results to the Saudi context is
Table 3 Pharmacoeconomic methodological and reporting recommendations.
The chosen perspective, time horizon, and analytical technique(s) should be clearly stated and justiﬁed
The alternatives being compared should be relevant and clearly described
Time horizon, and analytical technique(s) should be clearly stated and justiﬁed
The primary outcome measure(s) should be stated and justiﬁed in relation to the primary aim of the health intervention
The methods used to identify and select evidence should be described together with the main characteristics of selected evidence
The method used to estimate utility measures should be explained clearly
The methods for the estimation of resources quantities and unit costs described
Outcome measures should be presented with the relevant statistical measures of dispersion (mean, median, conﬁdence interval, etc.)
Signiﬁcant outcomes should be reported in aggregated and disaggregated forms.
Resource use data should be reported in physical units such as hours of staﬀ time, hospital days, number of consultations, and volume of drugs
Quantities of resources should be presented separately from the prices of those resources
The choice of discount rate, if performed, should be given and justiﬁed
For both the treatment and its comparator(s), the total costs and total beneﬁts arising from their use should be reported with their statistical
distribution
Incremental analysis is reported
Source Drummond et al., 2005.
192 S.A. AL Aqeel, M. Al-Sultannot acceptable (Drummond et al., 2009; Welte et al., 2004).
Saudi decision makers need to assess whether, and to what
extent, the pharmacoeconomic results from other settings ap-
plies to the Saudi setting.
To guide the reader through this section, three critical issues
are outlined: Is there pharmacoeconomic evaluation available
of sound methodology? Is the pharmacoeconomic evaluation
likely to be of value to Saudi Arabia decision makers? How
to adapt and transfer the pharmacoeconomic data? The ﬁrst
two questions will help the reader to decide if good quality
data are available and transferable and the third will discuss
issues to consider when transferring existing cost effectiveness
information to the Saudi context.
3.1. Is there pharmacoeconomic evaluation available and of
sound methodology?
If the literature search shows that published pharmacoeco-
nomic study exists, then it is important to ensure that it is of
good methodological quality, transparent, and adequately re-
ports on methods, and results. Table 3 presents the most
important methodological and reporting criteria. A useful tool
for decision makers is online databases that systematically
identify and describe economic evaluations, appraise their
quality and highlight their relative strengths and weaknesses.
One example is the economic evaluation database maintained
by the Centre for Reviews and Dissemination in the UK.
3.2. Is the pharmacoeconomics data likely to be of value to Saudi
decision makers?
Pharmacoeconomic evaluation might be of sound methodol-
ogy but not relevant to the Saudi context. For instance, if
either the new medication or the comparator(s) is (are) not rel-
evant in the Saudi setting, the existing pharmacoeconomic
evaluation results are irrelevant. This could be the case for
example, if the licensed indications are different from the Saudi
context, and this in turn affects the clinical applications of the
new product or those of the comparators. Furthermore, if the
patient population from existing pharmacoeconomic evalua-
tion is different from the Saudi population, then the pharma-
coeconomic evidence is not transferable.3.3. How to address transferability issues of evaluations from
other settings?
Where an evaluation already exists that is of good quality and
relevant to the Saudi decision makers, consideration should be
given to three main transferability issues: transferability of
clinical data, health state valuations or utility estimates, and
costs data.
As for the transferability of clinical data, the treatment ef-
fects (i.e., relative risk reduction) can be derived from a trial or
meta-analysis of trials conducted outside the Saudi context.
However, decision makers need to determine if the baseline
risk of patients within their own setting is the same as the base-
line risk of those patients considered within the existing evalu-
ation. They also need to consider the impact of local
epidemiological and demographic data on the baseline risk.
Some evidence indicates that the population health state
valuations might vary among different settings and countries
(Knies, 2009), therefore, the data used to generate utility mea-
sures, such as QALYS, should be collected from the Saudi
population. However, in view of lack of this type of research
in Saudi Arabia and if a decision needs to be made in a short
time period, data from other countries can be used. In such a
case sensitivity analysis should be used to test the sensitivity of
the study conclusions to various health state valuations.
Sources of feasible range to be used in sensitivity analysis are
explained in Section 2.4.
It is important to evaluate whether there is evidence of het-
erogeneity in patterns of resource utilisation between pub-
lished evidence and Saudi clinical practice. For instance,
there could be laboratory tests or patients counselling sessions
which are commonly applied in the published study setting but
not in the Saudi setting. This mean that costs associated with
the use of these extra resources should be excluded. This is
only possible if published evidence was transparent in report-
ing quantity of resources used and prices of those resources.
Other characteristics of existing pharmacoeconomic evalua-
tion, for which adjustment may be required, concern the per-
spective used and the impact this has on the approach for
estimating health care cost. For instance, if the analysis
adapted the society perspective then transportation and pro-
ductivity costs will be included, but from a hospital perspective
The use of pharmacoeconomic evidence to support formulary decision making in Saudi Arabia 193these costs are irrelevant. For this reason, exclusion of some
cost or outcome data might be required. Furthermore, differ-
ences in unit costs between countries make recalculation using
Saudi-speciﬁc cost data necessary. The discount rate should
also be adjusted using the previously suggested rate of 3%
and testing the sensitivity of results to a rate of 6% (WHO,
2003).
P&T decision makers can use decision-analytic models as
vehicles of pharmacoeconomic evaluation to address transfer-
ability issues. A model is a decision aid that accounts for events
over time and across populations, that is based on data drawn
from primary and/or secondary sources (Weinstein et al.,
2003). Decision makers could substitute relevant Saudi-speciﬁc
parameters, input the data into the model, and re-calculate new
ICERs. If Saudi parameters are not available then the use of
probabilistic or multivariate sensitivity analysis is useful for
assessment of variability of non-substituted parameters. The
most frequently encountered type of modelling techniques are
decision trees, in particular theMarkovmodels used for chronic
diseases requiring long-term evaluation. The basic model struc-
ture, assumptions, and parameters should be subtended by a
process of internal and external validation to ensure that they
are reasonable and accurately reﬂect the condition, process,
and the impact of the intervention and comparators in real life
(Philips et al., 2006). Those interested might beneﬁt from read-
ingmore in depth discussion ofmodelling techniques (Weinstein
et al., 2003; Philips et al., 2006). A good example where model-
ling techniques have been used to combine Saudi data and non-
Saudi data is a study by Ali et al. (2008) on the cost effectiveness
of conversion to biphasic insulin aspart 30 from human insulin.
4. Conclusion
In the light of lack of formal Saudi guidelines on pharmacoeco-
nomic evaluations, this paper should be the one of many re-
sources to guide decision makers when utilising
pharmacoeconomic evidence. The authors have recommenda-
tions to facilitate further the use of pharmacoeconomics. There
is a need for establishment of a national agency responsible for
commissioning and funding of pharmacoeconomic evaluation.
We also recommend that investments are made in the collection
of epidemiological and demographic data, plus data on clinical
practice patterns, resource use, costs, and health state valua-
tions. We also suggest that the Gulf countries with similar
health-care systems and clinical practice patterns should devel-
op partnerships to develop relevant regional databases and reg-
istries. When designing a pharmacoeconomic evaluation,
cooperation with a researcher who has experience in performing
such studies is recommended. Investment in education and
training of pharmacists in pharmacoeconomics is also required.
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